arrow_rightarrow_righticon_excelicon_pficon_ppticon_wordmagnifier

SUNDAY 20 MARCH 2022

For more information about the speaker, keywords presentation and photo please click on this buttons below:

Click here for Monday 21 March 2022

Sunday 20 Mar

08:30

Welcome

Plenary: State of the art Surgey

09:00

CRS and HIPEC for peritoneal metastases

Prof. Dr. Ignace de Hingh, Catharina Cancer Institute, the Netherlands

Biography
Professor Dr Ignace De Hingh, MD, PhD (1971) is surgical oncologist at the Catharina Cancer Institute in Eindhoven, the Netherlands. His clinical activities mainly focus on pancreatic cancer and the multi-disciplinary treatment of peritoneal metastases including CRS & HIPEC. He is involved in experimental, population-based and clinical studies aiming to improve the outcome of these patients and has co-authored over 340 peer-reviewed publications on these subjects. He is the past-president of the Dutch Peritoneal Oncology Group, founding member and secretary of the Dutch Pancreatic Cancer Group, executive board member of the Peritoneal Surface Oncology Group International (PSOGI), medical advisor of IKNL, professor at GROW Research School of the Maastricht University and participates in several national and international research projects.

Keywords
HIPEC
Peritoneal metastases
Colorectal cancer
Cytoreductive surgery

 

83-de_Hingh-Ignace

09:30

Rectal surgery anno 2022

Prof. Dr. Joep Knol, Zol Hopsital, Belgium

Biography
Joep Knol is Head of the Department of Colorectal Surgery at the ZOL Hospital (Ziekenhuis Oost-Limburg) in Genk, Belgium and is board member of the Belgian Section of Colorectal Surgery.
He also is a member of the European Association of Endoscopic Surgery.
He is active in minimally invasive colorectal surgery, including laparoscopic , robotic and transanal procedures. Along with the team in Genk, Joep has conducted many workshops on minimally invasive techniques and TaTME.
He has published multiple manuscripts on and is very much involved in the safe implementation of MIS.

Joep is National coordinator for AIS-channel and also co-founder of the iLappSurgery Foundation. The goal of this foundation is to develop online training modules in the field of minimal invasive surgery and to make such material available worldwide in the form of Apps. At this moment the App on TaTME, Liver surgery and the iLappVIP App (Video-In-Picture) are available. More info on www.ilappsurgery.com

Keywords
Rectum
MIS
Multidisciplinary

104-Knol-Joep

Parallel Symposia 1-5

Symposium 1: Liver metastasis-induction chemotherapy

10:15

Growth patterns of livermetastasis

Peter Vermeulen, GZA Hospitals St.Augustinus Antwerp, Belgium

10:30

Is there an optimal systemic induction regimen in patients with potentially resectable livermetastases?

Dr. Tinneke Buffart, Amsterdam UMC, the Netherlands

Biography
Tineke Buffart is a medical oncologist at the Amsterdam UMC specialized in treatment of patients with colorectal cancer. She has extensive experience in multidisciplinary treatment of these patients. In her research she is committed to optimize treatment and understanding of colorectal cancer and this ranges from clinical trials to translational and molecular studies.

Keywords
colorectal cancer
systemic treatment
metastases

69-Buffart-Tineke

10:45

Hepatic artery infusion pump chemotherapy- SUNSET OR SUNRISE

Dr. Michael D’Angelica, MSKCC, United States

Symposium 2: Prognostic value of histological features on disease recurrence

10:15

What are tumor deposits?

Prof. Dr. Iris Nagtegaal, RadboudUMC, the Netherlands

Biography
Iris Nagtegaal is professor of Gastrointestinal Pathology in Nijmegen, specialised in colorectal cancer. She is editor of the World Health Organisation of Digestive system tumors and member of the AJCC expert board for lower gastrointestinal cancers.

Keywords
colorectal cancer
pathology
tumor deposits
lymph node
vascular invasion

97-Nagtegaal-Iris

10:30

Value of lymph node metastasis on disease recurrence

Dr. Nick West, University Of Leeds, United Kingdom

Biography
Associate Professor of Pathology and Honorary Consultant in Gastrointestinal and Molecular Pathology. Research interest in clinical trials pathology, digital pathology and molecular/morphological biomarkers.

Keywords
Lymph node metastases
micrometastases

110-West-Nick

10:45

recurrence of disease from a biological perspective: CMS score/Immunoscore

Prof. Dr. Louis Vermeulen, Amsterdam UMC, the Netherlands

Biography
Louis Vermeulen (37) is professor in molecular oncology and a practicing medical oncologist at the Amsterdam University Medical Center. He is also a PI at the Oncode Institute.

He completed his PhD and medical training in Amsterdam, and spent several years as research fellow in the Cancer Research UK Institute in Cambridge, UK.

His work mainly focusses on gastro intestinal cancers, and ranges from fundamental biology to clinical trials. In particular, Louis has made relevant contributions to the classification of colorectal cancer in molecular subtypes, and our understanding of the role of stem cells in de development and growth of cancers.

Keywords
CMS
cancer heterogeneity
EMT
biomarkers

 

57-Vermeulen-Louis

Symposium 3: Peritoneal metastasis

10:15

Signet ring cell carcinoma; histopathological variants and survival after CRS-HIPEC

Dr. Petur Snaebjornsson, Netherlands Cancer Institute, the Netherlands

Biography
Dr. Petur Snaebjornsson is a pathologist at the Netherlands Cancer Institute in Amsterdam. His specialization is in the field of gastrointestinal pathology. Dr. Snaebjornsson studied medicine at the University of Iceland in Reykjavik. He specialized in pathology at the VU University Medical Center in Amsterdam. Dr. Snaebjornsson is an active researcher in the field of colorectal cancer (CRC) and his PhD was in the field of CRC pathology. He is a board member of the Dutch Colorectal Cancer Group (DCCG), member of the Dutch clinical guideline committee for CRC and board member of the lower gastrointestinal section of the Dutch Expertgroup on Gastrointestinal Pathology (EGIP).

Keywords
Signet ring cell carcinoma
Histopathology
CRS-HIPEC
Survival

79-Snaebjornsson-Petur

10:30

The role of Micro-Satellite and RAS/RAF mutational status as prognostic factors in colorectal peritoneal metastases

Dr. Antonio Sommariva, Veneto Institute of Oncology IOV-IRCCS, Italy

Biography
Surgical Oncologist (full time position) Surgical Oncology of the Esophagus and Digestive Tract Unit, Veneto Institute of Oncology IOV-IRCCS, Padova, Italy
Appointment Advanced Surgical Oncology Unit.
Research activity: Predictive and prognostic clinical and histopathological markers for solid tumors (peritoneal surface malignancies, sarcomas, melanoma).
Quality assurance in surgical oncology
Minimally invasive surgery
Clinical skills: Management and surgical treatment of abdominal tumors, sarcomas and melanoma
Loco-regional treatments (Hyperthermic Intraperitoneal Chemotherapy, HIPEC)
Membership; European Society of Surgical Oncology (ESSO)
Italian Society of Surgical Oncology SICO
Italian Melanoma Intergroup (IMI)

Keywords
colorectal
peritoneal
metastases
cytoreductive
surgery

77-Sommariva-Antonio

10:45

Imaging of peritoneal metastases

Dr. Max Lahaye, Netherlands Cancer Institute, the Netherlands

Biography
Max Lahaye is an abdominal radiologist, senior scientist, and clinical manager of the Department of Radiology at The Netherlands Cancer Institute, Amsterdam, with interests in MR imaging of rectal cancer and peritoneal metastases.

Keywords presentation
MRI
imaging
peritoneal metastases radiology

86-Lahaye-Max

Symposium 4: Discussion on a proposed assessment algorithm

10:15

Case 1

Prof. Gina Brown, Professor of Gastrointestinal Cancer Imaging

10:30

Case 2: How to diagnose and treat early rectal cancer using IEE and other modality

Prof.dr. Yutaka Saito, National Cancer Center Hospital, Chief of Endoscopy Division

Biography
Dr. Yutaka Saito is the Director of the Endoscopy Division at the National Cancer Center Hospital, Tokyo, Japan. He also has served as an attending Professor of Gastroenterology at Tokyo Medical University since April 2017.He has been invited to perform as a faculty member and live demonstrator in numerous countries. He was honored for an invited professor at Mayo Clinic, Rochester, Minnesota and Jacksonville, Florida in 2010, and at      Arizona in 2016. He was also commended for Basil Hirschowitz Master Endoscopist Award for advancing the art and science of endoscopy throughout the world in       2013 and Certificate of appreciation of Outstanding Reviewer for Gastrointestinal Endoscopy 2015-2017.

He has a wide spectrum of research exposure and interests including

  1. Chromo-magnification Colonoscopy
  2. Endoscopic Mucosal Resection and Endoscopic Submucosal Dissection for early gastrointestinal cancer
  3. Colon capsule endoscopy and artificial intelligence diagnosis for colorectal neoplasia
  4. Full-thickness resection and closure technique and device developments
  5. He has published more than 300 peer-reviewed English papers and textbooks

Keywords
Image-enhanced endoscopy (IEE)
JNET classification
Invasive pattern
Artificial intelligence (AI)
endoscopic submucosal dissection (ESD)

Yutaka Saito

10:45

Discussion on a proposed assesment algorithm

Prof.dr. Yutaka Saito, National Cancer Center Hospital, Chief of Endoscopy Division & Prof. Gina Brown, Professor of Gastrointestinal Cancer Imaging

Symposium 5: Clinical applications of circulating tumor DNA

10:15

ctDNA as biomarker for detection of minimal residual disease, assessment of adjuvant chemotherapy efficacy and for guiding surveillance

Prof. Claus Lindbjerg Andersen, Aarhus Universitetshospital, Denmark

Biography
Prof. Andersen’s research focuses on translation of basic molecular cancer knowledge into clinical tools. Prof. Andersen has developed a range of ultra-sensitive tools for tumor informed detection of ctDNA, both using digital PCR and sequencing (GUT 2016, ClinCan Res2017, SciTraMed 2017, ClinChem 2022). More recently, he has developed tumor agnostic detection methods exploiting DNA methylation patterns (ClinEpi 2019, ClinChem 2020) and tumor characteristic cell free DNA fragmentation patterns (Nature 2019). He has conducted several clinical studies addressing and documenting the potential clinical benefits of using ctDNA analysis in clinical decision-making (ClinCanRes 2017 & 2021, JAMA Onc 2019, JCO 2019, Mol Onc 2020, EurJCan 2022). Prof. Andersen is director of the “National Danish Research Centre for circulating tumor DNA guided treatment” which was established in 2020. The center initiates and coordinates national prospective clinical studies in all cancer types. He is member of the European Liquid Biopsy Society (lead: Clinical WG).

Keywords
ctDNA
colorectal cancer
minimal residual disease
Adjuvant therapy
Surveillance

 

128-Andersen-Claus_Lindbjerg

10:30

ctDNA as biomarker to detect minimal residual disease

Prof. Jeanie Tie, Peter MacCallum Cancer Centre, Australia

Biography
A/Prof Jeanne Tie is the lower gastrointestinal medical oncology and trials lead at the Peter MacCallum Cancer Centre, and senior research fellow in the Personalised Oncology Division at the Walter and Eliza Hall Institute of Medical Research. Her translational research focusses on personalising treatment for patients with colorectal cancer with prognostic and predictive biomarkers, in particular the clinical applications of circulating tumour DNA (ctDNA). She leads several ctDNA-based randomized clinical trials in colorectal cancer which aim to assess the clinical utility of ctDNA as a minimal residual disease marker to guide adjuvant treatment decision. She has published extensively in the field of colorectal cancer and serves or has served on the Australasian Gastrointestinal Trials Group (AGITG) Scientific Advisory Committee and Lower GI working party (Deputy Chair), Cancer Adjudication Committee for the ASPREE (Aspirin in Reducing Events in the Elderly) International study, ESMO (European Society for Medical Oncology) Gastro-Intestinal Tumours Faculty

Keywords
ctDNA
minimal residual disease
colorectal cancer

 

10:45

ctDNA as biomarker for monitoring treatment response

Dr. Remond Fijneman, Netherlands Cancer Institute, the Netherlands

Biography
Remond Fijneman is Principal Investigator within the Translational Gastrointestinal Oncology group at the Department of Pathology, Netherlands Cancer Institute (Amsterdam, the Netherlands) with special interest in colorectal cancer translational research. Research activities are focused on identification and validation of diagnostic, prognostic, predictive and disease monitoring biomarkers for colorectal cancer by molecular profiling at DNA, RNA and protein level, for translation into clinical applications. At present, several cell-free circulating tumor DNA multicenter studies are carried out concerning detection of minimal residual disease in stage II and stage III colon cancer and monitoring treatment response in metastatic colorectal cancer.

Keywords
colorectal cancer
cell-free circulating tumor DNA
prognostic biomarkers
predictive biomarkers
treatment response monitoring biomarkers

 

117-Fijneman-Remond

Parallel Symposia 6-10

Symposium 6: Oligometastatic disease

11:00

Sabr COMET Phase II trial

Prof. Suresh Senan, Amsterdam UMC, Cancer Center Amsterdam, the Netherlands

Biography
Suresh Senan is Professor of clinical experimental radiotherapy at the Amsterdam University Medical Centers. He trained in clinical oncology in the United Kingdom, before moving to The Netherlands. His research has focused on lung cancer, stereotactic radiotherapy, immune checkpoint inhibitors, and Magnetic Resonance-guided adaptive radiotherapy.

Keywords
oligometastatic disease
randomised trials
stereotactic ablative radiotherapy
progression-free survival

218-Senan-Suresh

11:15

CAIRO5: an update

Marinde Bond, UMC Utrecht, the Netherlands

Biography
After graduating as a Medical Doctor from the University of Amsterdam in October 2020 I started as a PhD candidate at the University Medical Center Utrecht. My PhD focuses on optimizing treatment strategies in colorectal cancer patients with liver-only metastases.

Keywords
Liver-only metastases
unresectable
induction therapy
liver expert panel
secondary surgery

64-Bond-Marinde

11:30

LUNA

t.b.c.

11:45

Selected Abstracts

Symposium 7: Adjuvant treatment of high risk Stage II CRC

11:00

Neoadjuvant chemotherapy for colon cancer

Prof. Dr. Dion Morton, University of Birmingham, United Kingdom

11:15

Who needs adjuvant chemotherapy for colon cancer

Dr. Miriam Koopman, UMC Utrecht, the Netherlands

Biography
Prof. dr. Miriam Koopman (1975) received her MD (cum laude) at the Radboud University Medical Center, Nijmegen, NL, and was trained as a medical oncologist at the University Medical Center Utrecht, NL. She was a trainee at the Dana Farber Cancer Institute, Boston USA in 2008. She received her PhD (cum laude) in 2009 on her thesis “Towards an optimal use of chemotherapy in advanced colorectal cancer (CRC) patients”. Since 2010 she has a tenured staff position at the department of Medical Oncology at the University Medical Center Utrecht, NL. In 2017 she was appointed as Professor of Medical Oncology, with focus on CRC. Her main focus of clinical/translational research concerns the improvement of the prognosis of CRC patients by optimizing treatment and developing prognostic/predictive (bio)markers, with the main objective of personalized care for CRC patients. In order to achieve this, she employs two strategies: 1) the conduct of prospective clinical studies, which focused on clinically relevant questions and which provided a spin-off with a wealth of clinical/translational research data, and 2) collecting real-life data, which reflect the true value of novel developments, give insight in the quality of care, and serve as a rich source for a variety of research that benefit a great diversity of stakeholders. She is the founder and current chair of the Dutch Prospective CRC cohort study (PLCRC), to which currently the majority of Dutch hospitals participate and which contains data from >12.000 patients. Since 2019 she is chair of the Dutch Colorectal Cancer Group (DCCG). In 2021 she was selected as chair for the newly established ESMO working group on Real World Data.

Keywords
adjuvant chemotherapy
high risk stage II
definition
outcome

111-Koopman-Miriam

11:30

Follow-up after surgery of high risk CRCs-spreker Primrose

Prof. John Pimrose, University of Southampton, United Kingdom

11:45

Selected Abstracts

t.b.c.

Symposium 8: Local treatment of liver metastasis

11:00

Liver transplantation for liver metastasis

Prof. Pål-Dag Line, Oslo University Hospital , Norway

Biography
Pål-Dag Line graduated with an MD from the University of Oslo in 1987 and a PhD in 1996. He is board certified in general, vascular and transplant surgery and is senior consultant surgeon in abdominal transplantation (liver, kidney, pancreas), HPB surgery, vascular surgery and microsurgery. He is head at the Department of Transplantation, Oslo University Hospital and Professor of Surgery at the University of Oslo. He has a particular clinical and scientific interest within HPB cancer, liver transplantation, abdominal vascular disease, and utilization of transplant surgical techniques in oncological surgery and has together with his coworkers been a pioneer in studying liver transplantation as a treatment option for non-resectable colorectal liver metastases.

Keywords
Liver transplantation
colorectal cancer
transplant criteria
prognostic scoring

202-Line-Pål-Dag

11:15

Rectal cancer with resectable liver metastasis

Diederik Hoppener, Erasmus MC, the Netherlands

11:30

How far can we go with liver resection: Limitations due to future liver remnant function

Erik Schadde, Rush University Medical Center Chicago/ Klinik Hirslanden Zürich/ St. Anna Hirslanden Luzern , USA

Biography
Erik Schadde divides his time between being a Transplant Surgeon and Surgical Oncologist at US Rush University in Chicago and a Consultant liver surgeon at the Swiss Hirslanden Hospitals in Zürich and Luzern. In his laboratory at the Institute of Physiology at the University of Zurich he works on mechanisms of rapid liver regeneration in large and small animal models. He started the International ALPPS registry in 2012 at the University of Zürich. Together with Ron Van Dam from Maastricht he initiated the international Dragon trials collaboration in 2017. Erik trained at Tufts University in Boston, did a transplant fellowship at University of Wisconsin-Madison and worked as a transplant surgeon and HPB surgeon in Kansas City, Saint Louis University and at the University of Zürich. His primary research focus is regenerative liver surgery for metastatic liver disease.

Keywords
Regenerative liver surgery, Liver metastases, ALPPS, Portal vein embolization (PVE), Portal Vein Ligation (PVL), Double embolization of portal and hepatic veins (PVE/HVE), Liver Venous Deprivation (LVD)

203-Schadde-Erik

11:45

Selected Abstracts

Sympsium 9: Histological evaluation of T1 CRCs

11:00

Controversies in assessing T1 CRCs

Dr. Maurice Loughrey, Belfast Health And Social Care Trust, Irland & Dr. Miangela Lacle, University Medical Center Utrecht, the Netherlands

Biography Dr. Maurice Loughrey
Dr. Maurice Loughrey is a Consultant Gastrointestinal Pathologist, practising in the Royal Victoria Hospital, Belfast, and an Honorary Senior lecturer at Queen’s University Belfast. His primary interests are in the pathology and biology of colorectal cancer and its precursor polyps. He has been pathology lead for the N. Ireland colorectal cancer screening programme since its inception in 2010 and is lead author of the Royal College of Pathologists (UK) and the International Collaboration for Cancer Reporting (ICCR) colorectal cancer datasets.

Biography Dr. Miangela Lacle
Dr. Miangela Lacle is a consultant Gastrointestinal Pathologist, practicing in the University Medical Center Utrecht, The Netherlands. Her primary interests are in the pathology and biology of early colorectal cancer. She has been pathology lead for the Dutch T1 CRC working group since it was founded in 2014.

Keywords
Pathology of pT1 CRCs
Lymphovascular invasion
Tumour budding
Margin assessment
Risk prediction models

44-Loughrey-Maurice

Dr. Maurice Loughrey

24-Lacle-Miangela

Dr. Miangela Lacle

11:45

Selected Abstracts

Sympsium 10: Organoids for therapy selection

11:00

Patient-derived organoids for forward and reverse translational cancer research

Prof. Nicola Imperial College London & The Institute of Cancer Research, London, United Kingdom

Biography
Professor Valeri is the Katherine and Douglas Longden Chair in Oncology in the Department of Surgery & Cancer at Imperial College London and Professor of Gastrointestinal Oncology at The Institute of Cancer Research and the Royal Marsden Hospital, London. He is co-Director of the Experimental Cancer Medicine Centre at Imperial College London and Associate Clinical Director for the Centre for Evolution and Cancer at The Institute of Cancer Research, London. He is a consultant medical oncologist at Imperial College NHS Trust and specialises in the treatment of gastrointestinal malignancies. Prof Valeri research focuses on the application of preclinical models and novel technological tools such as liquid biopsies to intercept, monitor and guide treatment in colorectal and gastroesophageal cancers.

Keywords
Precision oncology
forward and reverse translation
drug development

119-Valeri-Nicola

11:15

Patient-derived organoids as a predictive biomarker for treatment response in cancer patients

Emerens Wensink, University Medical Center Utrecht, the Netherlands

Biography
Completed a Bachelor of Science (Biochemistry) at Queen’s University in Kingston, Canada.
Studied medicine at University Utrecht and subsequently was an Internal Medicine resident for three years at the University Medical Center Utrecht (UMC Utrecht). Currently, am a PhD candidate at the UMC Utrecht, Cancer Center, under the supervision of Miriam Koopman, Onno Kranenburg and Jeanine Roodhart, with focus on personalizing treatment for patients with metastatic colorectal cancer.

Keywords
Organoids
Colorectal cancer
clinical trial
personalized medicine

180-Wensink-Emerens

11:30

Selected abstracts

11:45

Selected Abstracts

Sponsored Lunch sessions

Plenary: Treatment of T1 CRCs

13:00

Real life Recognition of T1 CRCs

Dr. Maria Pellise, Hospital Clinic of Barcelona

Biography
Dr Maria Pellisé (female), MD, PhD, Specialist in Gastroenterology, clinical coordinator of the Population Screening Programme and of the colorectal cancer MDT at the Hospital Clinic of Barcelona. Her main interest is colorectal cancer screening and surveillance. She is a national and international leader in advanced imaging and therapeutic endoscopy for colorectal high-risk patients. She has co-authored more than 170 scientific publications in international journals with more than 3950 citations (h-index 36 SCOPUS). She is currently associate professor at the Universitat de Barcelona, investigator at IDIBAPS, Chair of the Equity and Diversity WG at the ESGE and past-Editor from Endoscopy.

Keywords
pT1 CRC
endoscopy
screening
optical diagnosis
advanced imaging

43-Pellise-Maria

13:15

state of the art of Local excision of T1 CRCs

Dr. Mathieu Pioche, CHU de Lyon

13:30

How to treat high risk colon T1 CRC

MDT discussion with panel

Parallel symposiums 11- 15

Symposium 11: New developments Palliative systemic therapy

14:15

Exploring new therapies based on organoids – a novel triple therapy for RASmutant colorectal cancer.

Dr. Jeanine Roodhart, UMC Utrecht, the Netherlands

Biography
Jeanine Roodhart is a medical oncologist in the UMC Utrecht.
Expertise in colorectal cancer, translational research and early phase clinical trials.Research focus is bridging the translational gap (improving the translation of preclinical findings to the clinic) and personalisation of treatment by identifying biomarkers which can be used for optimal treatment selection (e.g. organoids, ctDNA, molecular subtypes) and identifying new treatment options for specific subgroups.

Keywords
organoids
RAS mutation
development of novel therapy
phase 1/2 trial
translational research

14:30

Development of HER2-targeted therapies for metastatic colorectal cancer

Yoshiaki Nakamura , National Cancer Center Hospital East, Japan

Biography
Yoshiaki Nakamura is now an Attending Physician in Translational Research Support Section / Department of Gastroenterology and Gastrointestinal Oncology. He is currently involved in several projects, mainly in the gastrointestinal oncology group of SCRUM-Japan, where he serves as principal investigator or sub-principal investigator for research related to liquid biopsy. He is also conducting some investigator-initiated clinical trials for rare subtype, such as HER2 positive colorectal cancer.

Keywords
HER2 amplification occurs in 1–4% of colorectal cancer.
Patients with HER2-positive colorectal cancer are less likely to benefit from anti-EGFR therapy.
HER2 amplification can be identified by circulating tumor DNA analysis as well as conventional tissue testing.
Dual HER2-blockade or anti-HER2 ADC have been developed for HER2-positive colorectal cancer.

 

68-Nakamura-Yoshiaki

14:45

Monitoring of RAS/RAF/EGFR mutations in circulating tumor DNA to guide anti-EGFR rechallenge with panitumumab in metastatic colorectal cancer patients: The CHRONOS trial

Prof. Alberto Bardelli, University Of Turin, Dept Of Oncology and Candiolo Cancer Institute IRCCS, Italy

Biography
After his undergraduate studies, he moved to the Ludwig Institute for Cancer Research in London where he obtained a Ph.D. in Biochemistry and Molecular biology from the University College London (UCL).
He moved to the United States in 1999 for a post-doctoral fellowship in the laboratory directed by Bert Vogelstein at the Howard Hughes Medical Institute, Johns Hopkins University (Baltimore). Here Bardelli began studying the genomics of cancer. The research that Vogelstein was conducting had just started to reveal the genetic profiles of colorectal cancer and tracing the molecular patterns of tumor progression. One of his most significant publications from that period identified for the first-time mutations in kinase genes (the kinome) that are associated with colorectal cancer.
As an independent investigator, he pioneered the combined use of genomics, patients’ avatars and liquid biopsies to accurately predict tumor’s response and resistance to targeted agents.
Bardelli’s group discovered that KRAS, NRAS and BRAF mutated colorectal cancer patients do not respond to anti EGFR antibodies. His work also led the development of diagnostic tests, based on the pioneering use of liquid biopsies. He showed that the analysis of circulating tumor DNA (liquid biopsies) allows monitoring tumor’s evolution and resistance to targeted therapies. The Bardelli’s lab was the first to pinpoint the emergence of KRAS/NRAS mutations in the blood of patients during EGFR blockade. These discoveries represent the first example of personalized therapies for colorectal cancer patients.
Overall, Bardelli has authored more than 250 scientific articles of which over 100 as an independent investigator.

Keywords
Metastatic colon cancer
anti EGFR antibody therapy
Liquid biopsy
Rechallenge
circulating tumor DNA

63-Bardelli-Alberto

Symposium 12: Treatment of recurrent rectal cancer

14:15

Extensive surgery and IORT in recurrent rectal cancer

Prof. Dr. Wim Ceelen, UZ Gent, Belgium

Biography
Wim P Ceelen graduated as a medical doctor in 1992 at Ghent University (Belgium) and later obtained his PhD at the same university with a doctoral thesis entitled ‘Neoadjuvant multimodal therapy in rectal cancer’. Currently, he is a staff surgeon in the department of Gastrointestinal Surgery at Ghent University Hospital and was appointed in 2010 as professor of Surgical Oncology at Ghent University. He is a Senior Clinical Investigator with the Flemish Research Foundation (FWO) and is director of the Laboratory of Experimental Surgery at Ghent University. His clinical interests include surgical oncology of the digestive tract, peritoneal metastases, and retroperitoneal sarcoma. His experimental research focuses on tumor physiology and biophysics, functional imaging of cancer, and novel approaches to intraperitoneal drug delivery. His teaching assignments include courses on Evidence Based Medicine for the surgical disciplines. He is (co)author of over 200 PubMed cited publications, edited three books, and is promoter of 13 completed and 5 ongoing PhD theses. He has served as president of the Belgian Society of Surgical Oncology and as Secretary General of the European Society for Surgical Research. He is a member of the Royal Belgian Academy of Medicine, the European Surgical Association, the EORTC GI group, the Cochrane collaboration GI group, the Society of Surgical Oncology (SSO), the European Society of Surgical Oncology (ESSO), and the American College of Surgeons. He currently serves as member of the Board of Directors of ESSO. Dr Ceelen is Editor-in -chief of Acta Chirurgica Belgica and associate editor of European Surgical Research, International Journal of Hyperthermia, Pleura and Peritoneum, and Frontiers in Surgical Oncology.

84-Ceelen-Wim

14:30

The role of neo-adjuvant treatment in locally recurrent rectal cancer

Dr. Pim Burger, Catharina Ziekenhuis Eindhoven, the Netherlands

14:45

Radiotherapy and systemic therapy for recurrent rectal cancer

Prof. Quentin Denost, Bordeaux University Hospital, France

Biography
Quentin Denost is Head of colorectal unit at the Magellan Center in Bordeaux University Hospital. He received his degree of Medicine in 2010 and his PhD in Biology and colorectal tissue engineering in 2014. He is active member of the European Society of ColoProctology (ESCP) and secretary general of the French GRECCAR group dedicated in research for rectal cancer. His clinical and research activities are both focussed on colorectal cancer and inflammatory bowel disease. His scientific publications are mainly focused on advanced rectal cancer, sphincter-saving surgery, locally recurrent rectal cancer and mini-invasive surgery.

Keywords
Reirradiation
Induction chemotherapy
Resectability
Quality of life
Long term oncological results

100-Denost-Quentin

Symposium 13: Treatment of liver metastasis with radio-embolisation

14:15

Introduction to radioembolization in mCRC

Dr. Macarena Rodríguez-Fraile, Clínica Universidad De Navarra, Spain

Biography
• Nuclear Medicine Physician at Clínica Universidad de Navarra, Pamplona, Spain. PhD
• Teacher at the School of Medicine of the University of Navarra
• More than 16 years experience with SIRT, being responsible of this area in NM since 2010.
• SIRT is is one of her preferential areas of dedication and research
• She has collaborated in more than 80 books and national and international journals

Keywords
Practical radioembolization
Basic concepts to consider in tumor boards

78-Rodríguez-Fraile-Macarena

14:30

Clinical indications and outcomes

Dr. Jon Bell, The Christie NHS Foundation Trust, United Kingdom

Biography
Dr Jon Bell is Head of the Department of Radiology at The Christie in Manchester, UK. He is an Interventional Radiologist and the Lead for Liver Directed Therapies. He is a member of the NICE Interventional Procedures Advisory Committee.

Keywords
Colorectal cancer
liver metastases
redioembolisation
dosimetry
outcomes

75-Bell-Jon

14:45

Future prospects of radioembolization

Prof. Dr. Marnix Lam, UMC Utrecht, the Netherlands

Biography
Prof. dr. Marnix G.E.H. Lam, Professor of Nuclear Medicine, Chief of Nuclear Medicine, University Medical Center Utrecht, department of Radiology and Nuclear Medicine, The Netherlands.
Marnix Lam is trained as a Nuclear Medicine Physician and Radiologist. He is a staff member of the department of Radiology and Nuclear Medicine in the UMC Utrecht since 2007. During his ‘Dutch Cancer Society (KWF)’ research fellowship on translational and clinical research (2010 – 2014), he completed a 2-year research fellowship at Stanford University. In 2013 he was appointed chief of Nuclear Medicine, and in 2016 he was appointed professor of Nuclear Medicine. Translational research in molecular medicine has been the scope of his scientific work, with a focus on oncology. The aim is to bring new radiopharmaceuticals to clinical practice. This specifically resulted in the introduction of new oncological treatment modalities in the Netherlands, such as bone seeking radiopharmaceuticals for the palliation of metastatic bone pain (153Sm-EDTMP, 188Re-HEDP, 223Ra-chloride), protein-receptor radionuclide therapy (177Lu-PSMA, 177Lu-HA-dotatate), and radioembolization for treatment of hepatic malignancies (90Y microspheres and 166Ho microspheres). Current research is focussed on dosimetry of therapeutic radiopharmaceuticals, image-guided treatment technology, alfa- and beta-emitting isotopes for therapeutic purposes, intra-arterial and intra-tumor treatment approaches, and radio-immunotherapy.

Keywords
SIRT: Radioembolization
TARE
yttrium
holmium

73-Lam-Marnix

Symposium 14: Optical diagnosis- Selection of cases for en bloc resections

14:15

When to perform en bloc resections (cut-offs)

Dr. Yara Backes, Meander MC, The Netherlands

Biography
Research interest: early colorectal cancer.
Participant T1 CRC working group.
Gastroenterologist in training.

Keywords
T1
En-bloc
optical diagnosis

35-Backes-Yara

14:30

When to go for primary surgery (cut-offs)

Prof. Helmut Messmann, Augsburg Medical Centre, Germany

14:45

AI instead of optical diagnosis by the endoscopist

Yuichi Mori, Digestive Disease Center, Showa University Northern Yokohama Hospital

Symposium 15: Biology of metastasis

14:15

Chromosomal instability and metastasis

Samuel Bakhoum, Memorial Sloan Kettering Cancer Center, United States

14:30

Genetic diversity in CRC metastases

Kamila Naxerova, Harvard Medical School, Massachusetts General Hospital, United States

Biography
Kamila Naxerova received her B.Sc. in Molecular Biotechnology with a specialization in bioinformatics from Heidelberg University in Germany, and her Ph.D. in Human Biology and Translational Medicine from Harvard University in Cambridge, MA. She completed her postdoctoral training with Dr. Stephen J. Elledge at Harvard Medical School. She is interested in using computational and high-throughput experimental approaches to elucidate the evolutionary history of human cancer.

Keywords
Metastasis
Cancer evolution

113-Naxerova-Kamila

14:45

Selected abstracts

15:00

Break

Parallel symposium 16-19

Symposium 16: Predicting treatment response

15:15

The predictive value of chromosomal loss of 18q in metastatic colorectal cancer treatment with Bevacizumab

Dr. Bauke Ylstra, Amsterdam UMC, the Netherlands

Biography
Ylstra specializes in techniques and methods that uncover the genomic traits of cancer. His quest is to make archival tumor tissues (formalin fixed paraffin embedded) available for research and molecularly accessible for diagnostics.

Dr. Ylstra graduated in 1995 with work he performed at the Departments of Genetics at the Free University in Amsterdam (NL) and the University of Vienna (A). He subsequently performed a post-doc at the University of California in Berkeley (CA, USA) focusing on the identification of stable mRNA molecules on a genome-wide scale. In 1998 he accepted a position at the University of California Comprehensive Cancer Center (CA, USA) in San Francisco; Since that moment he has been specializing in cancer genomics and was instrumental in the development and implementation of genome analysis methods for cancer research. Currently, he is the coordinator of the Genome Core of the Cancer Center Amsterdam of the VU University Medical Center (VUMC-CCA, NL). In Amsterdam his work focuses on genome techniques for personalized medicine. In particular, he focuses on techniques and methods (bio-informatics) for mutation and chromosomal copy number analysis by Whole Genome Sequencing (MPS). His pathological specialties include lymphoma, brain-, gastrointestinal- and head- and neck cancer.

Keywords
NGS
mCRC
bevacizumab
chromosomal deletion

52-Ylstra-Bauke

15:30

Whole genome sequencing of metastatic CRC: prior treatment effects, metastasis-specific features, potential clinical utility

Dr. Saskia Wilting, Erasmus MC Cancer Institute, the Netherlands

Biography
Saskia Wilting is a senior postdoctoral researcher at the department of Medical Oncology of the Erasmus University Medical Center Rotterdam, The Netherlands. Within this department, the work group Translational Cancer Genomics encompasses a strong translational research line which aims to improve the treatment of metastatic cancer patients. More specifically, her work focusses on the identification of molecular markers of cancer which allow for real-time monitoring of the disease in a patient’s blood and prediction of a patient’s response to treatment.

Keywords
Provide a comprehensive description of the molecular landscape of mCRC based on WGS and RNAseq data
1) Compare metastatic CRC to primary CRC
2) Investigate prior treatment effects
3) Associate molecular features to treatment outcome
4) Evaluate the potential clinical utility of WGS data for mCRC

15:45

Personalized treatmen in the clinical setting - how to do it?

Prof. Dr. Henk Verheul, Radboud UMC, Nijmegen

16:00

Selected Abstracts

Symposium 17: Organ preservation for early (T2-T3) rectal cancer

15:15

neoadjuvant radiotherapy for organ preservation

Simon Bach, University of Birmingham, United Kingdom

15:30

Chemoradiation for organ preservation

Femke Peters, Netherlands Cancer Institute, the Netherlands

Biography
Femke Peters is a radiation-oncologist, specialized in radiotherapy for gastro-intestinal cancers, especially rectal cancer, at the Department of Radiation Oncology at the Netherlands Cancer Institute, Amsterdam, the Netherlands. She has defended her PhD thesis at the University of Amsterdam in 2007 and completed her clinical training in Radiation Oncology at the Leiden University Medical Center in Leiden in 2014. She stayed as member of staff at Leiden University Medical Centre and combines patient care with clinical research. In 2019 she made the transfer to the Netherlands Cancer Institute.
The clinical research is focused on rectal cancer, mostly organ preserving therapy. She is a part of the international STAR-TREC research team and involved in the radiotherapy coordination and analysis of the TESAR trial.

Keywords
Rectal cancer
Organ preservation
Chemoradiation
Functional outcome

 

102-Peters-Femke

15:45

Neoadjuvant systemic treatment for organ preservation

Prof. Quentin Denost, Bordeaux University Hospital, France

Biography
Quentin Denost is Head of colorectal unit at the Magellan Center in Bordeaux University Hospital. He received his degree of Medicine in 2010 and his PhD in Biology and colorectal tissue engineering in 2014. He is active member of the European Society of ColoProctology (ESCP) and secretary general of the French GRECCAR group dedicated in research for rectal cancer. His clinical and research activities are both focussed on colorectal cancer and inflammatory bowel disease. His scientific publications are mainly focused on advanced rectal cancer, sphincter-saving surgery, locally recurrent rectal cancer and mini-invasive surgery.

Keywords
Induction chemotherapy
Consolidation chemotherapy
Systemic control
Patients selection

100-Denost-Quentin

16:00

Selected Abstracts

Symposium 18:

TRIALS for T1 CRCs

15:15

What are the important endpoints

Rodrigo Perez, Angelita & Joaquim Gama Institute, Hosp. Oswaldo Cruz - R. Treze de Maio, São Paulo, Brazil

15:30

PROMS for T1 CRCs

Jurriaan Tuynman, Amsterdam UMC, the Netherlands

15:45

What is the optimal study design

Xabier garcia-albeniz, Harvard University, United States

16:00

Selected Abstracts

Symposium 19

15:15

Intravital microscopy of CRC initiation and metastasis

Prof. Dr. Jacco van Rheenen, Oncode Institute and Netherlands Cancer Institute, the Netherlands

Biography
Jacco van Rheenen was originally trained in a variety of imaging techniques during his PhD with Dr. Kees Jalink at the Netherlands Cancer Institute. He was among the first to optimize imaging and develop software to quantitatively measure FRET on confocal microscopes.

Keywords
Intravital microscopy
CRC
metastasis
tumor initiation

121-van_Rheenen-Jacco

15:30

Gut vascular barrier impairment leads to intestinal bacteria dissemination and colorectal cancer metastasis to liver

Prof. Maria Rescigno, Humanitas University, Italy

Biography
Maria Rescigno is full professor, vice-rector and delegate to research at Humanitas University and group leader at Humanitas Research hospital, Milan. She graduated in Biology in 1990 at the University of Milan. From 1991 to 1994 she worked at the University of Cambridge, UK, in the Department of Biochemistry, as a visiting scholar. From 1995 to 1999, she worked at the National Research Council of Milan where she received her PhD in Pharmacology and toxicology in 1999. From 1999 to 2001 she worked at the University of Milano-Bicocca where she specialized in Applied Biotechnology. From 2001 to 2017 she has been the director of the Dendritic cell biology and immunotherapy Unit at the Department of Experimental Oncology at the European Institute of oncology. She was the first to show that dendritic cells actively participate to bacterial uptake in the gut and the existence of a gut vascular barrier that resembles the blood brain barrier. Her major field of interest is mucosal immunology, the microbiota and the development of new cancer immunotherapy strategies. She authored more than 170 publications in high impact journals including Science, Nature Immunol, Immunity, J. Exp. Med., Science TM. She was nominated EMBO young investigator in 2007. In 2008-2013 she was visiting professor at the University of Oslo. In 2011 Maria Rescigno won the Avon prize as ‘Woman symbol of the city of Milan’ and was elected EMBO member. She has been the recipient of three ERC grants (starting, proof-of-concept and consolidator). From 2019 she is member of the EMBO council. She seats in the technical and scientific board of several charities (AIRC, L’Oreal) and in different companies (Gelesis, MillBo, SiFi).
In 2016 Maria Rescigno has founded Postbiotica s.r.l. a spin-off of the University of Milan that exploits microbiota-derived metabolites as new pharmaceutical agents. In 2017 Postbiotica has won two competitions: Bioupper (Italy) and MyStart BCN (Spain).
H-index: 71

Keywords
Colorectal cancer
microbiota
metastasis
premetastatic niche
immune infiltration

127-Rescigno-Maria

15:45

Selected abstracts

16:00

Selected abstracts

16:30

Break

Key note lecture: Local treatment of liver metastasis

16:45

Surgical treatment of liver metastasis

Dr. Åsmund Avdem Fretland, Oslo University Hospital, Norway

Biography
Dr. Åsmund A. Fretland is born in Oslo but raised at a small farm in Lærdal, Western Norway. He did his early training at Hamar General Hospital and concluded surgical training at Oslo University Hospital, including a fellowship in HPB surgery. He trained minimally invasive HPB surgery with prof. Bjørn Edwin in Oslo.

Keywords
Liver
Metastasis
Colorectal
Cancer

 

88-Avdem_Fretland-Åsmund